Lung Cancer Exercise Training Study

This is an interventional treatment trial for Lung Cancer focused on measuring Exercise Intervention, Lung Cancer, 15-215 Read More

Inclusion Criteria:

• Signed informed consent prior to initiation of study-related procedures
• Age 21 - 80 years
• Weight < 205 kgs
• ECOG ≤ 1
• Diagnosed with histologically confirmed lung cancer, regardless of disease stage and receiving any prior line of any therapy in the context of metastatic disease
• An interval of at least three months following the completion of primary resection, if appropriate
• An interval of no longer than ten years following completion of primary therapy, if appropriate
• Life expectancy ≥ 4 months
• Performing less than 150 minutes of structured moderate-intensity or strenuous-intensity exercise per week
• Exercise intolerance (i.e., patients must have a VO2peak below that predicted for active age and sex-matched individuals)
• Willing to be randomized to one of the study arms
• Willing to commit to the study program and comply with all related protocol procedures

• Able to achieve an acceptable peak baseline CPET, as defined by any of the following criteria:

  • achieving a plateau in oxygen consumption, concurrent with an increase in power output;
  • a respiratory exchange ratio ≥ 1.10;
  • attainment of maximal predicted heart rate (HRmax) (i.e., within 10 bpm of age-predicted HRmax [HRmax = 220-Age[years]);
  • volitional exhaustion, as measured by a rating of perceived exertion (RPE) ≥ 18 on the BORG scale.
• Able to complete an acceptable baseline CPET in the absence of high risk ECG findings or other inappropriate response to exercise as determined by the PI.
• Ability to achieve and complete an acceptable baseline one-repetition maximum muscular strength test as defined by the effective execution of protocol-specific joint and muscle ranges of motion without remarkable signs or symptoms of pain, discomfort or distress.

Exclusion Criteria:

• Presence of a concurrent, actively treated other malignancy, or history of other malignancy treated within the past 3 years (other than non-melanoma skin cancer);
• Room air desaturation at rest ≤ 85%;
• Mental impairment leading to inability to cooperate.

• Any of the following absolute contraindications to cardiopulmonary exercise testing:

  • Acute myocardial infarction (within 3-5 days of any planned study procedures);
  • Unstable angina;
  • Uncontrolled arrhythmia causing symptoms or hemodynamic compromise;
  • Recurrent syncope;
  • Active endocarditis;
  • Acute myocarditis or pericarditis;
  • Symptomatic severe aortic stenosis;
  • Uncontrolled heart failure;
  • Acute (within 3 months) pulmonary embolus or pulmonary infarction;
  • Thrombosis of lower extremities;
  • Suspected dissecting aneurysm;
  • Uncontrolled asthma;
  • Pulmonary edema;
  • Respiratory failure;
  • Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis); or